TScan Therapeutics Ownership | Who Owns TScan Therapeutics?


OverviewForecastRevenueFinancialsChart

TScan Therapeutics Ownership Summary


TScan Therapeutics is owned by 43.68% institutional investors, 0.88% insiders, and 55.44% retail investors. Lynx1 capital management lp is the largest institutional shareholder, holding 5.51% of TCRX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.57% of its assets in TScan Therapeutics shares.

TCRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTScan Therapeutics43.68%0.88%55.44%
SectorHealthcare Stocks 46.80%8.14%45.06%
IndustryBiotech Stocks 44.70%7.99%47.31%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Lynx1 capital management lp5.22M5.51%$30.56M
Ecor1 capital5.00M5.27%$29.25M
Blackrock4.46M4.70%$26.10M
Adage capital partners gp4.40M4.64%$25.74M
Bvf inc/il2.99M3.15%$17.49M
Baker bros. advisors lp2.78M2.94%$16.29M
Vanguard group2.13M2.25%$12.48M
Propel bio management2.09M2.20%$12.21M
Deer management1.25M1.31%$7.29M
Alphabet1.08M1.14%$6.30M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Dc funds, lp630.00K61.20%$3.69M
Propel bio management2.09M7.92%$12.21M
Lynx1 capital management lp5.22M1.98%$30.56M
Deer management1.25M1.50%$7.29M
Stempoint capital lp845.07K1.45%$4.94M
Great point partners940.83K1.05%$5.50M
Ecor1 capital5.00M0.89%$29.25M
Bvf inc/il2.99M0.49%$17.49M
Simplify asset management1.05M0.41%$6.12M
Alphabet1.08M0.32%$6.30M

Top Buyers

HolderShares% AssetsChange
Blackrock4.46M0.00%2.76M
Great point partners940.83K1.05%940.83K
Stempoint capital lp845.07K1.45%845.07K
Lmr partners llp665.53K0.03%665.53K
Adage capital partners gp4.40M0.05%500.00K

Top Sellers

HolderShares% AssetsChange
Millennium management27.89K0.00%-364.23K
Paradigm biocapital advisors lp---353.89K
Susquehanna group, llp---297.90K
Goldman sachs group35.27K--224.88K
Alpine global management---137.49K

New Positions

HolderShares% AssetsChangeValue
Great point partners940.83K1.05%940.83K$5.50M
Stempoint capital lp845.07K1.45%845.07K$4.94M
Lmr partners llp665.53K0.03%665.53K$3.89M
Woodline partners lp163.49K0.01%163.49K$956.43K
Troluce capital advisors92.83K0.05%92.83K$543.07K

Sold Out

HolderChange
Federated hermes-56.00
Macquarie group-1.62K
Lazard asset management-2.55K
Cambridge investment research advisors-10.06K
Jump financial-10.79K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20247818.18%41,438,66220.84%431.60%4925.64%1344.44%
Mar 31, 20246622.22%34,293,0577.46%524.62%3914.71%980.00%
Dec 31, 20235468.75%31,912,88911.63%330.92%34112.50%5400.00%
Sep 30, 20233210.34%28,588,2312.22%600.45%1614.29%1-75.00%
Jun 30, 2023293.57%27,967,444189.29%1157.25%1416.67%433.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.37M2.57%-
BlackRock Health Sciences Term Trust1.05M1.97%-
Simplify Propel Opportunities ETF1.05M1.96%-
iShares Russell 2000 ETF967.48K1.83%-2.17K
BlackRock Health Sciences Opps Inv A681.01K1.29%-
Vanguard Institutional Extnd Mkt Idx Tr645.28K1.22%14.09K
Invesco Dorsey Wright SmallCap Momt ETF475.53K0.90%-
Fidelity Small Cap Index393.21K0.74%-12.58K
Fidelity Extended Market Index283.47K0.54%16.74K
abrdn Life Sciences Investors233.60K0.44%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 15, 2024Lynx1 Capital Management LP-Buy$4.11K
Sep 23, 2024Klencke Barbara-Buy$26.45K
Aug 23, 2024Klencke Barbara-Buy$28.45K
Aug 26, 2024Klencke Barbara-Buy$27.65K
Aug 23, 2024ZDRAVESKI ZORAN See RemarksSell$952.12K

Insider Transactions Trends


DateBuySell
2024 Q331
2024 Q23-
2024 Q1--
2023 Q43-
2023 Q3--

TCRX Ownership FAQ


Who Owns TScan Therapeutics?

TScan Therapeutics shareholders are primarily institutional investors at 43.68%, followed by 0.88% insiders and 55.44% retail investors. The average institutional ownership in TScan Therapeutics's industry, Biotech Stocks , is 44.70%, which TScan Therapeutics falls below.

Who owns the most shares of TScan Therapeutics?

TScan Therapeutics’s largest shareholders are Lynx1 capital management lp (5.22M shares, 5.51%), Ecor1 capital (5M shares, 5.27%), and Blackrock (4.46M shares, 4.70%). Together, they hold 15.48% of TScan Therapeutics’s total shares outstanding.

Does Blackrock own TScan Therapeutics?

Yes, BlackRock owns 4.70% of TScan Therapeutics, totaling 4.46M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 26.1M$. In the last quarter, BlackRock increased its holdings by 2.76M shares, a 162.61% change.

Who is TScan Therapeutics’s biggest shareholder by percentage of total assets invested?

Dc funds, lp is TScan Therapeutics’s biggest shareholder by percentage of total assets invested, with 61.20% of its assets in 630K TScan Therapeutics shares, valued at 3.69M$.

Who is the top mutual fund holder of TScan Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of TScan Therapeutics shares, with 2.57% of its total shares outstanding invested in 1.37M TScan Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools